Finoriq research workspace
Aprea Therapeutics, Inc. (APRE) Company Overview
Review a simplified SEC filing overview, TradingView market widgets, and reported line items for Aprea Therapeutics, Inc. (APRE).
Company Snapshot
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
- Company
- Aprea Therapeutics, Inc. (APRE)
- Ticker
- APRE
- Market Cap
- $8.4M
- Latest Price
- $0.677
- Industry
- Biotech & Pharma
Aprea Therapeutics, Inc. (APRE) Current Valuation Metrics
Static valuation preview for Aprea Therapeutics, Inc. (APRE). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -130.1% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -130.8% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 0.22x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.